Novavax Gains US FDA Advisory Committee Endorsement, But So Does Myocarditis Risk Statement
Executive Summary
Vaccines and Related Biological Products Advisory Committee members agree another option should be made available, especially if Novavax's protein-based design could encourage those who refused the mRNA vaccines to be inoculated.
You may also be interested in...
All Myocarditis, Pericarditis Cases With COVID-19 Vaccines Now Must Be Reported To VAERS
The change to three vaccine emergency use authorizations was made quietly, most recently for the Novavax vaccine.
Novavax’s Vaccine Switched Manufacturing Facilities Multiple Times Prior To EUA
One switch raised questions, but by the time the COVID-19 vaccine reached commercial scale, the changes were considered minor.
Novavax EUA Justified By US FDA With Claims Of COVID Vaccine Supply Constraints
The agency also includes a myocarditis warning in the fact sheet for the first protein-based COVID-19 vaccine to reach the US market.